Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24367684 | 0.72 | NR4A2 (0.35) | — | |
| SCHEMBL24365040 | 0.70 | CHRM2 (0.38) | ALDH1A1 | |
| SCHEMBL31390348 | 0.69 | RIPK2 (0.46) | ALDH1A1HSD17B10 | |
| SCHEMBL31390358 | 0.68 | DYRK1A (0.47) | — | |
| SCHEMBL926871 | 0.67 | NAMPT (0.46) | NAMPTALDH1A1HSD17B10 | |
| SCHEMBL22013891 | 0.67 | ALDH1A1 (0.46) | NAMPTALDH1A1HSD17B10 | |
| SCHEMBL22072755 | 0.66 | NAMPT (0.34) | NAMPTALDH1A1HSD17B10 | |
| SCHEMBL31145103 | 0.66 | CHRNB4 (0.41) | NAMPTALDH1A1HSD17B10 | |
| SCHEMBL12637458 | 0.65 | ALDH1A1 (0.42) | NAMPTALDH1A1HSD17B10 | |
| SCHEMBL12637453 | 0.65 | NAMPT (0.47) | NAMPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NAMPT 1439/4885ALDH1A1 128/4885HSD17B10 1375/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NAMPT 1439/4885ALDH1A1 128/4885HSD17B10 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.